Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
19 December 2025
19 December 2025
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.